Skip to NavigationSkip to content

Pfizer’s coronavirus vaccine shows moderate side-effects in clinical study

Published on 16/09/20 at 12:19pm
Photo by Lauri Silvennoinen

Pfizer has said that participants in a late-stage trial for its COVID-19 vaccine candidate have shown mild to moderate side effects. 

The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with BioNTech. Over 12,000 study participants have received a second dose of the vaccine. 

Unlike the AstraZeneca study which was forced to come to a halt recently, the Pfizer trial is not being paused as the symptoms shown are not severe or life-threatening. 

Fatigue was the most common side-effect, but researchers do not yet know how much of the affected had received the vaccine or a placebo; 36% of the 18 to 64 age group and 27% of the 65 to 84 group reported this symptom. After fatigue, the most common reported side-effects were headaches, muscle pain, joint pain and chills. 

In a company call, Dr Kathrin Janson, the Head of Research at Pfizer, said that researchers would “notify us if they had any safety concerns and have not done that to date.”

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches